The Experts below are selected from a list of 300 Experts worldwide ranked by ideXlab platform

Göran Rybo - One of the best experts on this subject based on the ideXlab platform.

  • A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine Contraceptive Device in the treatment of idiopathic menorrhagia.
    American journal of obstetrics and gynecology, 1991
    Co-Authors: Ian Milsom, Kerstin Andersson, Björn Andersch, Göran Rybo
    Abstract:

    Treatment with flurbiprofen (100 mg twice a day for 5 days), tranexamic acid (1.5 gm three times a day for 3 days and 1 gm twice a day for another 2 days), and an intrauterine Contraceptive Device releasing 20 μg levonorgestrel per day was compared in women with idiopathic menorrhagia. The menstrual blood loss during two control periods in 15 women subsequently treated with flurbiprofen and tranexamic acid was 295 ± 52 ml and 203 ± 25.2 ml in the 16 women later fitted with a levonorgestrel-releasing intrauterine Contraceptive Device. Menstrual blood loss was reduced by all three forms of treatment. The reduction in menstrual blood loss expressed as a percentage of the mean of two control cycles for each form of treatment was as follows: flurbiprofen, 20.7% ± 9.9%; tranexamic acid, 44.4% ± 8.3%; levonorgestrel-releasing intrauterine Contraceptive Device after 3 months, 81.6% ± 4.5%; levonorgestrel-releasing intrauterine Contraceptive Device after 6 months, 88.0% ± 3.1%; levonorgestrel-releasing intrauterine Contraceptive Device after 12 months, 95.8% ± 1.2%. The reduction in menstrual blood loss achieved by the levonorgestrel-releasing intrauterine Contraceptive Device was greater than that recorded with flurbiprofen ( p p p

M Rafique - One of the best experts on this subject based on the ideXlab platform.

  • vesical calculus a complication of intravesical migration of intrauterine Contraceptive Device
    International Urogynecology Journal, 2002
    Co-Authors: M Rafique
    Abstract:

    Intravesical migration of an intra-uterine Contraceptive Device (IUCD) in a 28-year-old woman resulted in recurrent urinary tract infections. She received antibiotic treatment from her general practitioner but had no investigations done. Later on she became pregnant and investigations revealed that the thread of IUCD was missing and there was a vesical calculus. After she had delivered the baby, a pelvic X-ray was taken and showed a vesical calculus on the IUCD. Both calculus and IUCD were removed cystoscopically.

A. Singer - One of the best experts on this subject based on the ideXlab platform.

Pergoran Larsson - One of the best experts on this subject based on the ideXlab platform.

  • prolonged use of intrauterine Contraceptive Device as a risk factor for tubo ovarian abscess
    Acta Obstetricia et Gynecologica Scandinavica, 2009
    Co-Authors: Georgios Charonis, Pergoran Larsson
    Abstract:

    Objective. The intrauterine Contraceptive Device (IUCD) is the most preferred method of reversible contraception in the world today. The Swedish Medical Products Agency currently recommends that women who had a copper IUCD inserted around age 40 do not need to have it extracted until one year after the menopause. Design. Retrospective study. Setting. Skovde Central Hospital, Sweden. Population. All 114 women receiving in-patient treatment for pelvic inflammatory disease (PID) over five years between January 2001 and December 2005. Methods. Comparison between cases of tubo-ovarian abscesses and salpingitis with focus on the effects of IUCDs used continually for andgt; 5 years after insertion. Main outcome measures. Age-adjusted risk of PID within or after five years of use, microbiological findings in blood, intraabdominal pus, cervical secretions or on extracted IUCDs. Results. There were 31 cases of tubo-ovarian abscesses, 63 of salpingitis, four of endometritis, and 16 of mild genital infection. When comparing women with the same IUCD andgt; 5 years to women having the same IUCD andlt;= 5 years, the risk of tubo-ovarian abscess was higher than the risk of salpingitis (OR 19.7; 95% CI 4.5-87.2). The risk remained significant after adjustment for age, both on multiple regression analysis (OR 13.5; 95% CI 2.5-72.9) and in stratified analysis for the age group 35-50 years (OR 12.0; 95% CI 1.8-81.7). Blood or abdominal cultures from patients operated upon were positive in 47.7% of the sampled cases. Intestinal tract microbes and upper respiratory tract microbes were more common than sexually transmitted infection microbes. Conclusions. The current Medical Products Agency recommendation that a woman nearing the end of her reproductive phase can safely use the same IUCD for a period exceeding five years is challenged.

Ian Milsom - One of the best experts on this subject based on the ideXlab platform.

  • A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine Contraceptive Device in the treatment of idiopathic menorrhagia.
    American journal of obstetrics and gynecology, 1991
    Co-Authors: Ian Milsom, Kerstin Andersson, Björn Andersch, Göran Rybo
    Abstract:

    Treatment with flurbiprofen (100 mg twice a day for 5 days), tranexamic acid (1.5 gm three times a day for 3 days and 1 gm twice a day for another 2 days), and an intrauterine Contraceptive Device releasing 20 μg levonorgestrel per day was compared in women with idiopathic menorrhagia. The menstrual blood loss during two control periods in 15 women subsequently treated with flurbiprofen and tranexamic acid was 295 ± 52 ml and 203 ± 25.2 ml in the 16 women later fitted with a levonorgestrel-releasing intrauterine Contraceptive Device. Menstrual blood loss was reduced by all three forms of treatment. The reduction in menstrual blood loss expressed as a percentage of the mean of two control cycles for each form of treatment was as follows: flurbiprofen, 20.7% ± 9.9%; tranexamic acid, 44.4% ± 8.3%; levonorgestrel-releasing intrauterine Contraceptive Device after 3 months, 81.6% ± 4.5%; levonorgestrel-releasing intrauterine Contraceptive Device after 6 months, 88.0% ± 3.1%; levonorgestrel-releasing intrauterine Contraceptive Device after 12 months, 95.8% ± 1.2%. The reduction in menstrual blood loss achieved by the levonorgestrel-releasing intrauterine Contraceptive Device was greater than that recorded with flurbiprofen ( p p p